Physician profile
Brenda Bourassa
NPI 1184726978
$1,349.61
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $432 · 2020: $153 · 2021: $360 · 2022: $404.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $316.44 | 2019-2022 | |
| Mallinckrodt Hospital Products INC. | $313.56 | 2020-2022 | |
| Opko Pharmaceuticals, LLC | $172.29 | 2019-2020 | |
| Amgen INC. | $145.27 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $101.98 | 2021-2022 | |
| Mallinckrodt Enterprises LLC | $74.13 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $59.67 | 2021-2022 | |
| Akebia Therapeutics INC | $51.30 | 2019-2020 | |
| Glaxosmithkline, LLC. | $43.85 | 2021 | |
| Vifor Pharma, INC. | $22.02 | 2020 | |
| Aurinia Pharma U.S., INC. | $19.69 | 2021 | |
| Baxter Healthcare | $15.55 | 2019 | |
| Fresenius USA Marketing, INC. | $13.86 | 2022 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brenda Bourassa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.